cm6b05357_si_001.pdf (221.05 kB)
High-Density Lipoprotein-like Magnetic Nanostructures (HDL-MNS): Theranostic Agents for Cardiovascular Disease
journal contribution
posted on 2017-02-24, 00:00 authored by Vikas Nandwana, Soo-Ryoon Ryoo, Shanthi Kanthala, Kaylin M. McMahon, Jonathan S. Rink, Yue Li, Subbu S. Venkatraman, C. Shad Thaxton, Vinayak P. DravidWe
report the development of potential theranostic agents for cardiovascular
disease that are based on high-density lipoprotein-like magnetic nanostructures
(HDL-MNS). The HDL-MNS offer prospects for diagnosis via noninvasive
magnetic resonance imaging for anatomic detection and also serve as
effective cholesterol efflux agents to address atherosclerotic vascular
lesions. The HDL-MNS are synthesized by adding phospholipids and the
HDL-defining apolipoprotein A1 to the surface of magnetic nanostructures
(MNS) to mimic some aspects of natural HDL particles. From a diagnostic
perspective, HDL-MNS show a 5 times higher contrast (r2 relaxivity up to 383 mM–1 s–1) in magnetic resonance imaging (MRI) than commercially available
T2 MRI contrast agents (e.g., Ferumoxytol). Internalization
of HDL-MNS by macrophage cells was confirmed by transmission electron
microscopy (TEM), energy dispersive X-ray spectroscopy (EDX), inductive-coupled
plasma mass spectrometry (ICP-MS), and successfully imaged via MRI.
Also, the HDL-MNS particles show capacity to induce cholesterol efflux
(∼4.8%) from macrophage cells comparable to natural HDL (∼4.7%),
providing a pathway to prevent and treat cardiovascular disease via
reverse cholesterol transport. The ability to image macrophage cells
that have internalized HDL-MNS along with the cholesterol efflux capacity
demonstrates the potential of the HDL-MNS particles as theranostic
agents.